Introduction

Alphyn Capital's Q2 2026 investor letter brought attention to AnaptysBio (ANAB) as a special-situation opportunity. The letter illustrated how corporate restructuring can reshape a biotech investment thesis, especially when a company transitions from a broad pipeline to a focused royalty model. This approach highlights the firm's shift toward investments with clearer theses, expected returns, and defined exit strategies.

What Happened

In April 2026, AnaptysBio completed a separation that moved its clinical pipeline into a new entity, leaving behind a streamlined royalty business with fewer than ten employees. The core asset is a royalty on Jemperli, GSK's cancer immunotherapy. Royalty terms start at 8% and escalate to 25% on annual sales above $2.5 billion. In 2025, Jemperli generated more than $1.1 billion in sales, and GSK has guided toward exceeding $2.7 billion. A key legal development saw the Delaware court dismiss a GSK counterclaim that could have cut the royalty rate in half, reinforcing confidence in the situation's upside potential with limited downside risk. As of September 2026, the stock closed at $56.60 per share, reflecting a market capitalization of approximately $1.68 billion, with a one-month return of -0.67% and a 52-week gain of 272.75%.

Why This Matters

The restructured model offers investors exposure to a marketed oncology drug's commercial performance with limited operational risk. The court's decision reinforces the stability of the royalty terms, making AnaptysBio a notable example of how special-situation investing can uncover value in companies transitioning to focused royalty streams. For biotech portfolios, this provides a royalty-backed alternative to traditional pipeline-dependent bets. The case also underscores the importance of clear investment theses and exit strategies, especially after prior management missteps where holding positions past their initial rationale changed led to disappointing longer-term results.

Key Takeaways

  • AnaptysBio's value is anchored in contracted future royalties, net cash, and an authorized share-repurchase program, supporting a base-case valuation of $55 to $65 per share.
  • A strengthened royalty agreement or favorable ruling could push intrinsic value toward $70 to $105 per share.
  • The Q2 2026 letter emphasized that every holding now has a defined thesis, expected return, and exit strategy, reflecting a disciplined approach after prior management flaws.
  • With 34 hedge funds holding the position at quarter-end, the stock retains institutional interest, though it remains outside the most crowded 40 names in the space.
  • Investors seeking royalty-backed biotech exposure without full clinical risk may find ANAB particularly relevant.

Conclusion

Alphyn Capital's letter uses AnaptysBio as a case study in how special-situation analysis can reveal value beyond traditional metrics. The combination of a secured royalty stream, resolved legal landscape, and clear exit parameters makes ANAB a compelling example of structured biotech investing. As always, due diligence on sales trajectory and market conditions remains essential, but the framework outlined provides a template for evaluating similar situations in the sector.